Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
This study is ongoing, but not recruiting participants.
First Received: April 24, 2002   Last Updated: June 23, 2005   History of Changes
Sponsor: ICOS-Texas Biotechnology
Collaborators: ICOS Corporation
Texas Biotechnology Corporation
Information provided by: ICOS-Texas Biotechnology
ClinicalTrials.gov Identifier: NCT00034307
  Purpose

This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV). The purpose of this study is to evaluate the safety and effectiveness of two different doses of sitaxsentan, compared to placebo (inactive treatment) for the treatment of pulmonary arterial hypertension. Patients who complete this trial may be eligible to take part in an extension trial (Protocol FPH01-X). Eligible patients who receive placebo in the 12-week study cross over to receive sitaxsentan for the extension trial.


Condition Intervention Phase
Pulmonary Hypertension
Drug: sitaxsentan sodium
Phase II
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension

Resource links provided by NLM:


Further study details as provided by ICOS-Texas Biotechnology:

Estimated Enrollment: 180
  Eligibility

Ages Eligible for Study:   16 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. NYHA Class II, III or IV
  2. 16 to 75 years of age
  3. Specific peak VO2 range
  4. PPH, PAH due to connective tissue disease or select congenital heart disease
  5. Qualifying cardiac catheterization
  6. History of CXR and qualifying pulmonary function test
  7. History of qualifying ventilation-perfusion lung scan
  8. History of qualifying echocardiogram
  9. Women of childbearing potential must use contraceptives
  10. Stable dose of corticosteroids if prescribed

Exclusion Criteria:

  1. Significant lung disease
  2. Chronic liver disease
  3. Uncontrolled sleep apnea
  4. History of specific types of left heart disease
  5. Any disorder that compromises ability to give informed consent
  6. Uncontrolled sleep apnea
  7. Inability to perform bicycle exercise test
  8. On-going treatment with an experimental drug or device within the last 30 days
  9. HIV infection
  10. Specific liver dysfunction
  11. Chronic renal disease
  12. Pregnancy/Nursing
  13. Chronic active hepatitis B or C
  14. Chronic Flolan or Tracleer use within the last 30 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00034307

  Hide Study Locations
Locations
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
Harbor-UCLA Medical Center
Torrance, California, United States, 90502
University of Southern California Hospital, Ambulatory Health Sciences
Los Angeles, California, United States, 90033
United States, Colorado
University of Colorado/ Health Science Center
Denver, Colorado, United States, 80262
The Children's Hospital
Denver, Colorado, United States, 80218
United States, Georgia
Medical College of Georgia
Augusta, Georgia, United States, 30912
Emory University Hospital - McKelvey Lung Transplantation Center
Atlanta, Georgia, United States, 30322
Dekalb Medical Center
Decatur, Georgia, United States, 30033
United States, Illinois
Rush Heart Institute, Center for Pulmonary Heart Disease, Rush-Presbyterian-St. Luke's Medical Center
Chicago, Illinois, United States, 60612
United States, Louisiana
LSU - School of Medicine
New Orleans, Louisiana, United States, 70112
United States, Maine
Maine Medical Center
Portland, Maine, United States, 04102
United States, Maryland
John Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Michigan
University of Michigan Hospital, Division of Cardiology
Ann Arbor, Michigan, United States, 48109
United States, Minnesota
Mayo Clinic - Division of Cardiovascular Disease
Rochester, Minnesota, United States, 55905
United States, New York
Columbia Presbyterian Medical Center
New York, New York, United States, 10032
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Division of Cardiology - The Ohio State University Medical Center
Columbus, Ohio, United States, 43210
The Cleveland Clinic Foundation, Department of Pulmonary and Critical Care
Cleveland, Ohio, United States, 44195
United States, Oregon
Oregon Health Sciences
Portland, Oregon, United States, 97201
United States, Pennsylvania
University of Pittsburgh Medical Center, CHF/Transplantation Cardiology
Pittsburgh, Pennsylvania, United States, 15213
United States, Rhode Island
Pulmonary Division - Rhode Island Hospital
Providence, Rhode Island, United States, 02903
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
United States, Texas
Baylor College of Medicine Pulmonary & Critical Care Section
Houston, Texas, United States, 77030
United States, Wisconsin
University of Wisconsin Medical School
Milwaukee, Wisconsin, United States, 53215
Canada, Quebec
SMBD Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
ICOS-Texas Biotechnology
ICOS Corporation
Texas Biotechnology Corporation
Investigators
Study Director: Lyn Frumkin, M.D., Ph.D. ICOS Corporation
  More Information

Additional Information:
No publications provided

Study ID Numbers: FPH01/FPH01-X
Study First Received: April 24, 2002
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00034307     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Respiratory Tract Diseases
Hypertension, Pulmonary
Lung Diseases
Vascular Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on November 25, 2009